These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells. Nemethova V; Babiakova P; Teglasova B; Uhelska L; Babelova A; Selc M; Jakic K; Mitrovsky O; Myslivcova D; Zackova M; Poturnayova A; Batorova A; Drgona L; Razga F Am J Physiol Cell Physiol; 2024 Jul; 327(1):C184-C192. PubMed ID: 38826137 [TBL] [Abstract][Full Text] [Related]
8. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F; Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665 [TBL] [Abstract][Full Text] [Related]
9. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells. Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776 [TBL] [Abstract][Full Text] [Related]
10. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. Chen M; Gallipoli P; DeGeer D; Sloma I; Forrest DL; Chan M; Lai D; Jorgensen H; Ringrose A; Wang HM; Lambie K; Nakamoto H; Saw KM; Turhan A; Arlinghaus R; Paul J; Stobo J; Barnett MJ; Eaves A; Eaves CJ; Holyoake TL; Jiang X J Natl Cancer Inst; 2013 Mar; 105(6):405-23. PubMed ID: 23446755 [TBL] [Abstract][Full Text] [Related]
11. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition. Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553 [TBL] [Abstract][Full Text] [Related]
12. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Bewry NN; Nair RR; Emmons MF; Boulware D; Pinilla-Ibarz J; Hazlehurst LA Mol Cancer Ther; 2008 Oct; 7(10):3169-75. PubMed ID: 18852120 [TBL] [Abstract][Full Text] [Related]
13. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490 [TBL] [Abstract][Full Text] [Related]
14. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150 [TBL] [Abstract][Full Text] [Related]
15. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. Bellodi C; Lidonnici MR; Hamilton A; Helgason GV; Soliera AR; Ronchetti M; Galavotti S; Young KW; Selmi T; Yacobi R; Van Etten RA; Donato N; Hunter A; Dinsdale D; Tirrò E; Vigneri P; Nicotera P; Dyer MJ; Holyoake T; Salomoni P; Calabretta B J Clin Invest; 2009 May; 119(5):1109-23. PubMed ID: 19363292 [TBL] [Abstract][Full Text] [Related]
17. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells. Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884 [TBL] [Abstract][Full Text] [Related]
18. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia. Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601 [No Abstract] [Full Text] [Related]
19. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy. Ferri C; Bianchini M; Bengió R; Larripa I Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia. Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]